Cadence, Exela Pharma Sciences LLC neurology news
The U.S. District Court for the District of Delaware ruled in favor of Cadence in a patent infringement suit against Exela regarding Cadence's Ofirmev acetaminophen injection for pain and fever. In 2011, Cadence filed Cadence Pharmaceuticals Inc. et al. v. Exela Pharma Sciences LLC et al., alleging that Exela's ANDA submission for a generic version of Ofirmev infringes U.S. Patent Nos. 6,028,222 and 6,992,218. Cadence said the court rejected Exela's claims that the patents are invalid and ruled that the ANDA infringes both patents. The court ordered the parties to submit a proposed order by Nov. 21 to enter final judgment for Cadence, including appropriate remedy. The '222 patent expires in August 2017, and the '218 patent expires in June 2021. ...